Live Breaking News & Updates on Dostarlimab Plus Chemotherapy

Stay updated with breaking news from Dostarlimab plus chemotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dostarlimab Plus Chemo Continues to Demonstrate Strong Clinical Efficacy in Advanced NSCLC

Dostarlimab plus chemotherapy elicited a higher objective response rate and showcased a numerical improvement in overall survival compared with pembrolizumab and chemotherapy in patients with treatment-naïve, nonsquamous non–small cell lung cancer. ....

Comunidad Autonoma De Cataluna , Eli Lilly , Roche Genentech , Daiichi Sankyo , Noemi Reguart , Pharma Mar , Solange Peters , Merck Serono , Foundation Medicine , Boehringer Ingelheim , Bristol Myers Squibb , Department Of Oncology , University Hospital Of Lausanne , European Lung Cancer Congress , Thoracic Malignancies Program , University Hospital , Hospital Clinic , Blueprint Medicines , Merck Sharp , Phosplatin Therapeutics , Seattle Genetics , Lung Cancer Congress , Dostarlimab Plus Chemotherapy , Patients With Treatment Naïve , Nonsquamous Non Small Cell Lung Cancer , Perla Trial ,

CHMP Recommends Dostarlimab Plus Chemotherapy in dMMR/MSI-H Advanced/Recurrent Endometrial Cancer

The Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended the approval of dostarlimab plus chemotherapy for the treatment of adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer. ....

European Medicines Agency , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , New England Journal , Dostarlimab Plus Chemotherapy , Patients With Mismatch Repair Deficient Microsatellite Instability High Primary Advanced Or Recurrent Endometrial Cancer , Ruby Trial , Heshama Abdullah ,

FDA Grants Priority Review to Dostarlimab Plus Chemo for dMMR/MSI-H Endometrial Cancer

The FDA has accepted and granted priority review to a supplemental biologics license application seeking the approval of dostarlimab plus chemotherapy for use in adult patients with mismatch repair–deficient/microsatellite instability–high primary advanced or recurrent endometrial cancer. ....

New England Journal , Dostarlimab Plus Chemotherapy , Endometrial Cancer , Msi H , Gynecologic Cancer , Priority Review , Mismatch Repair Deficient , Microsatellite Instability High , Ruby Study , Ruby Engot Eng Gog3031 Nsgo , New England Journal Of Medicine ,